NO333579B1 - Anvendelse av kopolymer 1 for fremstilling av en farmasoytisk sammensetning for behandling av inflammatoriske tarmsykdommer. - Google Patents

Anvendelse av kopolymer 1 for fremstilling av en farmasoytisk sammensetning for behandling av inflammatoriske tarmsykdommer. Download PDF

Info

Publication number: NO333579B1
Authority: NO; Norway
Prior art keywords: mice; disease; treatment; colitis; copolymer
Prior art date: 2003-01-21

Application number

NO20053860A

Other languages

English (en)

Norwegian (no)

Other versions

NO20053860L (no

NO20053860D0 (no

Inventor

Rina Ahoroni

Ruth Amon

Basak Kayhan

Original Assignee

Yeda Res & Dev

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-01-21

Filing date

2005-08-18

Publication date

2013-07-15

2005-08-18 Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev

2005-08-18 Publication of NO20053860D0 publication Critical patent/NO20053860D0/no

2005-10-20 Publication of NO20053860L publication Critical patent/NO20053860L/no

2013-07-15 Publication of NO333579B1 publication Critical patent/NO333579B1/no

Links

238000011282 treatment Methods 0.000 title claims abstract description 66
229920001577 copolymer Polymers 0.000 title claims abstract description 36
208000022559 Inflammatory bowel disease Diseases 0.000 title claims description 32
239000008194 pharmaceutical composition Substances 0.000 title claims description 11
238000002360 preparation method Methods 0.000 title claims description 3
208000011231 Crohn disease Diseases 0.000 claims abstract description 16
206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 8
201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 8
238000002347 injection Methods 0.000 claims description 18
239000007924 injection Substances 0.000 claims description 18
108090000765 processed proteins & peptides Proteins 0.000 abstract description 34
102000004196 processed proteins & peptides Human genes 0.000 abstract description 26
229920001184 polypeptide Polymers 0.000 abstract description 16
108010072051 Glatiramer Acetate Proteins 0.000 abstract description 9
FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 abstract description 7
229960003776 glatiramer acetate Drugs 0.000 abstract description 7
230000002757 inflammatory effect Effects 0.000 abstract description 4
208000014151 Stomatognathic disease Diseases 0.000 abstract 1
241000699670 Mus sp. Species 0.000 description 112
206010009887 colitis Diseases 0.000 description 61
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 56
201000010099 disease Diseases 0.000 description 55
NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 50
230000006698 induction Effects 0.000 description 35
230000000694 effects Effects 0.000 description 26
235000001014 amino acid Nutrition 0.000 description 24
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 22
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 22
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 21
238000011803 SJL/J (JAX™ mice strain) Methods 0.000 description 21
235000004279 alanine Nutrition 0.000 description 21
150000001413 amino acids Chemical class 0.000 description 21
230000009467 reduction Effects 0.000 description 21
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 20
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 20
239000004472 Lysine Substances 0.000 description 20
230000006378 damage Effects 0.000 description 20
235000018977 lysine Nutrition 0.000 description 20
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 19
210000004027 cell Anatomy 0.000 description 19
235000013922 glutamic acid Nutrition 0.000 description 19
239000004220 glutamic acid Substances 0.000 description 19
230000004044 response Effects 0.000 description 19
235000002374 tyrosine Nutrition 0.000 description 19
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 16
241000699666 Mus <mouse, genus> Species 0.000 description 16
210000001072 colon Anatomy 0.000 description 16
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 14
108060008682 Tumor Necrosis Factor Proteins 0.000 description 14
102100040247 Tumor necrosis factor Human genes 0.000 description 14
BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 14
102000004887 Transforming Growth Factor beta Human genes 0.000 description 13
108090001012 Transforming Growth Factor beta Proteins 0.000 description 13
ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 13
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 12
230000004054 inflammatory process Effects 0.000 description 12
230000028327 secretion Effects 0.000 description 12
238000011725 BALB/c mouse Methods 0.000 description 11
230000000968 intestinal effect Effects 0.000 description 11
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 10
206010061218 Inflammation Diseases 0.000 description 10
230000000112 colonic effect Effects 0.000 description 10
238000000034 method Methods 0.000 description 10
239000013543 active substance Substances 0.000 description 9
239000000427 antigen Substances 0.000 description 9
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
210000000936 intestine Anatomy 0.000 description 9
230000009257 reactivity Effects 0.000 description 9
229920001897 terpolymer Polymers 0.000 description 9
230000004580 weight loss Effects 0.000 description 9
238000002474 experimental method Methods 0.000 description 8
239000004471 Glycine Substances 0.000 description 7
208000025865 Ulcer Diseases 0.000 description 7
230000035611 feeding Effects 0.000 description 7
230000036269 ulceration Effects 0.000 description 7
239000004475 Arginine Substances 0.000 description 6
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
235000003704 aspartic acid Nutrition 0.000 description 6
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000011081 inoculation Methods 0.000 description 6
210000004989 spleen cell Anatomy 0.000 description 6
230000004083 survival effect Effects 0.000 description 6
206010012735 Diarrhoea Diseases 0.000 description 5
230000009286 beneficial effect Effects 0.000 description 5
210000001165 lymph node Anatomy 0.000 description 5
210000000952 spleen Anatomy 0.000 description 5
102000004127 Cytokines Human genes 0.000 description 4
108090000695 Cytokines Proteins 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
238000010171 animal model Methods 0.000 description 4
230000037396 body weight Effects 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
238000007433 macroscopic evaluation Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
230000008506 pathogenesis Effects 0.000 description 4
230000001575 pathological effect Effects 0.000 description 4
230000008569 process Effects 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
229920005604 random copolymer Polymers 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
238000012360 testing method Methods 0.000 description 4
208000023275 Autoimmune disease Diseases 0.000 description 3
238000011740 C57BL/6 mouse Methods 0.000 description 3
150000008574 D-amino acids Chemical class 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
206010020565 Hyperaemia Diseases 0.000 description 3
101100273635 Rattus norvegicus Ccn5 gene Proteins 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
230000008859 change Effects 0.000 description 3
238000003304 gavage Methods 0.000 description 3
230000008595 infiltration Effects 0.000 description 3
238000001764 infiltration Methods 0.000 description 3
244000005700 microbiome Species 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
238000004806 packaging method and process Methods 0.000 description 3
230000035755 proliferation Effects 0.000 description 3
230000008929 regeneration Effects 0.000 description 3
238000011069 regeneration method Methods 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
208000004998 Abdominal Pain Diseases 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
208000009329 Graft vs Host Disease Diseases 0.000 description 2
102000006354 HLA-DR Antigens Human genes 0.000 description 2
108010058597 HLA-DR Antigens Proteins 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
150000008575 L-amino acids Chemical class 0.000 description 2
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241001529936 Murinae Species 0.000 description 2
159000000021 acetate salts Chemical class 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
229940038717 copaxone Drugs 0.000 description 2
239000003651 drinking water Substances 0.000 description 2
235000020188 drinking water Nutrition 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
230000000762 glandular Effects 0.000 description 2
208000024908 graft versus host disease Diseases 0.000 description 2
230000002519 immonomodulatory effect Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000002134 immunopathologic effect Effects 0.000 description 2
239000012678 infectious agent Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000000463 material Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000005087 mononuclear cell Anatomy 0.000 description 2
201000006417 multiple sclerosis Diseases 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
235000008729 phenylalanine Nutrition 0.000 description 2
230000000770 proinflammatory effect Effects 0.000 description 2
230000009696 proliferative response Effects 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
238000011084 recovery Methods 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000008961 swelling Effects 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
210000004876 tela submucosa Anatomy 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
206010000050 Abdominal adhesions Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000002881 Colic Diseases 0.000 description 1
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 description 1
206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 1
206010061818 Disease progression Diseases 0.000 description 1
239000004097 EU approved flavor enhancer Substances 0.000 description 1
208000018522 Gastrointestinal disease Diseases 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
101001018097 Homo sapiens L-selectin Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102100033467 L-selectin Human genes 0.000 description 1
102000043131 MHC class II family Human genes 0.000 description 1
108091054438 MHC class II family Proteins 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
206010028124 Mucosal ulceration Diseases 0.000 description 1
102000047918 Myelin Basic Human genes 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
206010034650 Peritoneal adhesions Diseases 0.000 description 1
239000012980 RPMI-1640 medium Substances 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
210000000447 Th1 cell Anatomy 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000030741 antigen processing and presentation Effects 0.000 description 1
-1 aromatic amino acid Chemical class 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000003246 corticosteroid Substances 0.000 description 1
229960001334 corticosteroids Drugs 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
230000005750 disease progression Effects 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000000945 filler Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000019264 food flavour enhancer Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
230000004077 genetic alteration Effects 0.000 description 1
231100000118 genetic alteration Toxicity 0.000 description 1
239000011491 glass wool Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
230000035876 healing Effects 0.000 description 1
238000010562 histological examination Methods 0.000 description 1
230000008076 immune mechanism Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
229940124589 immunosuppressive drug Drugs 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
208000028774 intestinal disease Diseases 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007737 ion beam deposition Methods 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
230000008693 nausea Effects 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
208000020911 optic nerve disease Diseases 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
230000002688 persistence Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
210000003289 regulatory T cell Anatomy 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
210000004988 splenocyte Anatomy 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
229940021747 therapeutic vaccine Drugs 0.000 description 1
230000008719 thickening Effects 0.000 description 1
230000019432 tissue death Effects 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
239000003053 toxin Substances 0.000 description 1
238000002627 tracheal intubation Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

NO20053860A 2003-01-21 2005-08-18 Anvendelse av kopolymer 1 for fremstilling av en farmasoytisk sammensetning for behandling av inflammatoriske tarmsykdommer. NO333579B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US44113603P	2003-01-21	2003-01-21
PCT/IL2004/000054 WO2004064717A2 (fr)	2003-01-21	2004-01-20	Copolymere 1 pour le traitement de maladies enteriques inflammatoires

Publications (3)

Publication Number	Publication Date
NO20053860D0 NO20053860D0 (no)	2005-08-18
NO20053860L NO20053860L (no)	2005-10-20
NO333579B1 true NO333579B1 (no)	2013-07-15

Family

ID=32771907

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20053860A NO333579B1 (no)	2003-01-21	2005-08-18	Anvendelse av kopolymer 1 for fremstilling av en farmasoytisk sammensetning for behandling av inflammatoriske tarmsykdommer.

Country Status (14)

Country	Link
US (1)	US8008258B2 (fr)
EP (1)	EP1592384B1 (fr)
AU (1)	AU2004206120B2 (fr)
CA (1)	CA2513567C (fr)
DK (1)	DK1592384T3 (fr)
ES (1)	ES2397836T3 (fr)
MX (1)	MXPA05007711A (fr)
NO (1)	NO333579B1 (fr)
NZ (1)	NZ569331A (fr)
PT (1)	PT1592384E (fr)
RU (1)	RU2339397C2 (fr)
SI (1)	SI1592384T1 (fr)
WO (1)	WO2004064717A2 (fr)
ZA (1)	ZA200505733B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US7429374B2 (en) *	2001-12-04	2008-09-30	Teva Pharmaceutical Industries, Ltd.	Process for the measurement of the potency of glatiramer acetate
US7655221B2 (en)	2004-05-07	2010-02-02	Peptimmune, Inc.	Methods of treating disease with random copolymers
JP5495490B2 (ja) *	2004-05-07	2014-05-21	アレストレーディングエスエイ	ランダム共重合体を用いる疾患の治療方法
US9107864B2 (en)	2004-06-07	2015-08-18	Qu Biologics Inc.	Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en)	2004-06-07	2013-08-06	Qu Biologics Inc.	Tissue targeted antigenic activation of the immune response to treat cancers
HRP20160455T1 (hr) *	2004-09-09	2016-07-15	Yeda Research And Development Co., Ltd.	Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
JP2008528589A (ja) *	2005-02-02	2008-07-31	テバファーマシューティカルインダストリーズリミティド	水素化分解を用いてポリペプチド混合物を作成する方法
US20100167983A1 (en) *	2007-10-22	2010-07-01	Teva Pharmaceutical Industries, Ltd.	Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
JP2011529078A (ja) *	2008-07-25	2011-12-01	ザ・ジョンズ・ホプキンス・ユニバーシティー	自己免疫疾患を治療および予防するための方法および組成物
NZ598661A (en)	2009-08-20	2013-02-22	Yeda Res & Dev	Low frequency glatiramer acetate therapy
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) *	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
SG187201A1 (en) *	2010-07-26	2013-02-28	Qu Biolog Inc	Immunogenic anti-inflammatory compositions
CA2814500A1 (fr)	2010-10-11	2012-04-19	Teva Pharmaceutical Industries Ltd	Marqueurs biologiques a base de cytokine comme marqueurs biologiques predictifs de la reponse clinique pour l'acetate de glatiramere
WO2012143924A1 (fr)	2011-04-21	2012-10-26	Mapi Pharma Ltd.	Pentapolymère statistique pour le traitement de maladies auto-immunes
WO2013009885A2 (fr)	2011-07-11	2013-01-17	Momenta Pharmaceuticals, Inc.	Evaluation de diéthylamide de copolymère
US8575198B1 (en)	2011-09-07	2013-11-05	Momenta Pharmaceuticals, Inc.	In-process control for the manufacture of glatiramer acetate
HK1200274A1 (en)	2011-10-10	2015-08-07	Teva Pharmaceutical Industries Ltd.	Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
HK1213830A1 (zh)	2012-10-10	2016-07-15	Teva Pharmaceutical Industries Ltd.	用於预测醋酸格拉替雷临床反应的生物标志物
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10251946B2 (en)	2014-05-02	2019-04-09	Qu Biologics Inc.	Anti-microbial immunomodulation
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
WO2018002930A1 (fr)	2016-06-30	2018-01-04	Stem Cell Medicine Ltd.	Traitement d'une maladie intestinale inflammatoire avec du glatiramère à action prolongée et des cellules souches dérivées du tissu adipeux
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh)	2016-08-31	2019-07-05	Mapi医药公司	包含醋酸格拉替雷的储库系统
CN110382052A (zh)	2017-03-26	2019-10-25	Mapi医药公司	用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
EP3624816A4 (fr)	2017-05-15	2021-02-24	Stem Cell Medicine Ltd.	Traitement de la sclérose en plaques avec des cellules souches dérivées du tissu adipeux
EP3624815A4 (fr)	2017-05-15	2021-01-20	Stem Cell Medicine Ltd.	Traitement de la sclérose en plaques avec un glatiramère à action prolongée et des cellules souches dérivées du tissu adipeux

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA27776C2 (uk) *	1991-05-31	2000-10-16	Пфайзер Інк.	Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців
IL113812A (en) *	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use
US5858964A (en) *	1995-04-14	1999-01-12	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
US6214791B1 (en) *	1997-01-10	2001-04-10	Yeda Research And Development Co. Ltd.	Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en)	1998-07-23	2002-02-10	Yeda Res & Dev	Treatment of autoimmune conditions with copolymer 1 and related copolymers
WO2000005249A2 (fr) *	1998-07-23	2000-02-03	The President And Fellows Of Harvard College	Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
DK2239269T3 (da)	1998-09-25	2013-04-29	Yeda Res & Dev	Anvendelse af peptider afledt af copolymer-1 som molekylvægtsmarkører
WO2000020010A1 (fr) *	1998-10-02	2000-04-13	Yeda Research And Development Co., Ltd.	Administration en jours alternes de copolymer 1 destine au traitement de maladies autoimmunes
AU775073C (en) *	1998-11-12	2007-05-03	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US20010044416A1 (en) *	2000-01-20	2001-11-22	Mccluskie Michael J.	Immunostimulatory nucleic acids for inducing a Th2 immune response
IL150895A0 (en) *	2000-02-18	2003-02-12	Teva Pharma	Oral, nasal and pulmonary formulations of copolymer-1
AU2003204344A1 (en) *	2002-05-23	2003-12-11	Milder, Dan George	Compositions and methods for the treatment of autoimmune diseases and neurological disorders
HRP20160455T1 (hr)	2004-09-09	2016-07-15	Yeda Research And Development Co., Ltd.	Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene

2004
- 2004-01-20 RU RU2005126412/15A patent/RU2339397C2/ru not_active IP Right Cessation
- 2004-01-20 SI SI200431983T patent/SI1592384T1/sl unknown
- 2004-01-20 AU AU2004206120A patent/AU2004206120B2/en not_active Ceased
- 2004-01-20 US US10/543,764 patent/US8008258B2/en not_active Expired - Fee Related
- 2004-01-20 NZ NZ569331A patent/NZ569331A/xx not_active IP Right Cessation
- 2004-01-20 MX MXPA05007711A patent/MXPA05007711A/es active IP Right Grant
- 2004-01-20 CA CA2513567A patent/CA2513567C/fr not_active Expired - Fee Related
- 2004-01-20 EP EP04703462A patent/EP1592384B1/fr not_active Expired - Lifetime
- 2004-01-20 PT PT47034624T patent/PT1592384E/pt unknown
- 2004-01-20 ZA ZA200505733A patent/ZA200505733B/en unknown
- 2004-01-20 ES ES04703462T patent/ES2397836T3/es not_active Expired - Lifetime
- 2004-01-20 WO PCT/IL2004/000054 patent/WO2004064717A2/fr not_active Ceased
- 2004-01-20 DK DK04703462.4T patent/DK1592384T3/da active
2005
- 2005-08-18 NO NO20053860A patent/NO333579B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
US8008258B2 (en)	2011-08-30
SI1592384T1 (sl)	2013-03-29
NZ569331A (en)	2010-08-27
ZA200505733B (en)	2006-10-25
CA2513567A1 (fr)	2004-08-05
AU2004206120B2 (en)	2009-09-24
WO2004064717A2 (fr)	2004-08-05
PT1592384E (pt)	2013-01-28
WO2004064717A3 (fr)	2005-10-13
EP1592384A4 (fr)	2008-12-31
EP1592384A2 (fr)	2005-11-09
US20060264354A1 (en)	2006-11-23
NO20053860L (no)	2005-10-20
RU2339397C2 (ru)	2008-11-27
DK1592384T3 (da)	2012-12-17
AU2004206120A1 (en)	2004-08-05
CA2513567C (fr)	2012-10-23
EP1592384B1 (fr)	2012-10-31
ES2397836T3 (es)	2013-03-11
NO20053860D0 (no)	2005-08-18
MXPA05007711A (es)	2005-09-30
RU2005126412A (ru)	2006-01-27

Legal Events

Date	Code	Title	Description
2019-08-26	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
NO333579B1 (no)	2013-07-15	Anvendelse av kopolymer 1 for fremstilling av en farmasoytisk sammensetning for behandling av inflammatoriske tarmsykdommer.
AU775073C (en)	2007-05-03	Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US7420033B2 (en)	2008-09-02	Composition of lactoferrin related peptides and uses thereof
ES2952044T3 (es)	2023-10-26	Sistemas de depósito que comprenden acetato de glatiramer
JP2002515853A (ja)	2002-05-28	低投与量の▲ｉｉ▼型コラーゲンによる慢性関節リウマチの治療
JP2019196363A (ja)	2019-11-14	リポソームに基づく免疫療法
KR0159046B1 (ko)	1998-11-16	포유류의 자기면역 포도막망막염의 치료 또는 예방방법
CA2512735A1 (fr)	2004-07-22	Vaccin sous forme de gouttes ophtalmiques contenant un copolymere-1 destine a l'immunisation therapeutique
US20060276390A1 (en)	2006-12-07	Combined treatments comprising synthetic peptide copolymers for preventing graft rejection
WO2008075365A1 (fr)	2008-06-26	Compositions et procédés de traitement de la dégénérescence rétinienne liée à l'âge
WO2010075824A1 (fr)	2010-07-08	Utilisation de peptide de type apl pour le traitement de maladies inflammatoires intestinales et pour le diabète de type i
Thurau et al.	2002	Oral tolerance for treating uveitis—new hope for an old immunological mechanism
US7053043B1 (en)	2006-05-30	Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
JP7242059B2 (ja)	2023-03-20	シェーグレン症候群の治療用ペプチド
WO2005055920A2 (fr)	2005-06-23	Compositions et methodes de traitement de troubles psychiatriques
EP1701730B1 (fr)	2013-08-21	Methode et vaccin comprenant le copolymere 1 pour le traitement de troubles psychiatriques
Aharoni et al.	2008	The therapeutic effect of TV-5010 in a murine model of inflammatory bowel disease—Dextran induced colitis
Arnon	2006	Copolymer 1 and Related Peptides as Immunomodulating Agents
IL176217A (en)	2011-10-31	Pharmaceutical compositions comprising copolymer 1 for treatment of post-traumatic stress disorder (ptsd), schizophrenia, depression or bipolar disorder